Trazodone Regulatory Status: US, EU, Canada, UK

FDA Approval and US Regulatory Standing

The US Food and Drug Administration approved trazodone hydrochloride in 1981 under the brand name Desyrel for the treatment of major depressive disorder (MDD). That approval predated the modern era of selective serotonin reuptake inhibitors (SSRIs) by several years, placing trazodone among the earlier second-generation antidepressants available to American clinicians [1].

Original NDA and Label Scope

The original new drug application was filed by Mead Johnson (later absorbed by Bristol-Myers Squibb). The approved labeling restricts the indication to MDD in adults. No supplemental NDA has been submitted or approved for insomnia, anxiety, or any other condition [2]. The FDA's Orange Book lists dozens of generic manufacturers holding approved abbreviated new drug applications (ANDAs) for immediate-release tablets in 50 mg, 100 mg, 150 mg, and 300 mg strengths.

Off-Label Prescribing Volume

Despite the narrow label, trazodone became one of the most prescribed medications for insomnia in the United States. A 2005 analysis by Mendelson noted that trazodone had already surpassed purpose-built hypnotics in sleep-related prescribing volume, driven largely by clinician concern over the abuse liability and tolerance patterns associated with benzodiazepine receptor agonists [3]. IQVIA data from 2022 estimated approximately 26 million dispensed prescriptions for trazodone in the US, with the majority written at doses of 50 to 100 mg, well below the 150 to 400 mg antidepressant range [4]. The FDA has not objected to this practice but has also not modified the label to reflect it.

Scheduling and Prescription Requirements

Trazodone is not classified as a controlled substance under the US Controlled Substances Act. It carries no DEA schedule. Prescribers do not need a DEA number specifically for trazodone, and pharmacies face no controlled-substance dispensing restrictions. This stands in contrast to commonly prescribed sleep medications like zolpidem (Schedule IV) and suvorexant (Schedule IV) [5]. That regulatory distinction partly explains trazodone's appeal for providers treating insomnia in patients with substance use histories.

European Regulatory Framework

Trazodone's European authorization follows a decentralized pathway. Individual EU member states granted national marketing authorizations rather than the European Medicines Agency (EMA) issuing a single centralized approval. The originator brand Trittico, manufactured by Aziende Chimiche Riunite Angelini Francesco (now Angelini Pharma), holds authorizations across Italy, Germany, Austria, and numerous other member states [6].

Approved Indications Across the EU

The approved indication in most EU countries is major depressive disorder, sometimes with the additional notation "with or without associated anxiety." Italy's Agenzia Italiana del Farmaco (AIFA) approved Trittico Contramid, a once-daily extended-release formulation, in 2009. This formulation uses a proprietary Contramid matrix that delivers trazodone over 24 hours, allowing once-daily dosing at 150 to 300 mg [7]. The extended-release product is designed for depression, not insomnia. No EU national authority has approved trazodone specifically for insomnia as a standalone indication.

Prescription Classification

Across all 27 EU member states, trazodone is classified as a prescription-only medicine. It does not appear on any EU controlled substance schedule. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) does not list trazodone among substances of concern, reflecting its low abuse potential [8].

Formulation Availability

European patients have access to formulation options not available in the US market. The Contramid extended-release tablet is authorized in Italy, Portugal, and several other southern and central European markets but has never received FDA approval. Drop formulations (oral solution) are also available in select EU countries, providing dosing flexibility that the US market's tablet-only field does not offer [6].

Health Canada Authorization

Health Canada approved trazodone for the treatment of depression, listing it on the Prescription Drug List under Schedule IV of the Food and Drug Regulations. The Drug Product Database shows multiple approved generic manufacturers including Apotex, Teva Canada, and Pharmascience, all producing immediate-release tablets [9].

Approved Strengths and Indications

Available Canadian strengths mirror the US market: 50 mg, 75 mg, 100 mg, and 150 mg immediate-release tablets. The approved indication is limited to depression. Health Canada's product monograph for trazodone includes warnings about orthostatic hypotension, priapism, and cardiac arrhythmias but does not reference insomnia treatment [9].

Off-Label Sleep Use in Canadian Practice

Canadian prescribing patterns for trazodone closely track the US experience. A 2014 cross-sectional study using IMS Health data found that trazodone was the most commonly prescribed agent for insomnia in Canadian primary care, with over 60% of prescriptions written for sleep rather than depression [10]. The Canadian Sleep Society's 2023 position paper acknowledged off-label trazodone use for insomnia but noted that randomized controlled trial evidence supporting this indication remains limited, citing short study durations and small sample sizes [11].

Regulatory Distinctions from the US

One practical difference: Health Canada requires that the product monograph explicitly list "depression" as the sole authorized indication, meaning that any insomnia-related prescribing is clearly documented as off-label in the dispensing record. Canadian pharmacists are required to note when a prescribed use falls outside the approved monograph, a transparency mechanism that does not have a direct US equivalent [9].

UK MHRA Regulatory Status

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) classifies trazodone as a prescription-only medicine (POM). Following Brexit, the MHRA assumed full regulatory authority over trazodone's marketing authorization, previously held under EU mutual recognition procedures [12].

Post-Brexit Authorization

UK marketing authorizations for trazodone were grandfathered under the Northern Ireland Protocol and the Medicines and Medical Devices Act 2021. The brand Molipaxin (trazodone hydrochloride) has been available in the UK since the 1980s, originally marketed for depression. Current MHRA authorization covers 50 mg and 100 mg capsules and a 50 mg/5 mL liquid formulation [12].

NICE Guidance and Positioning

The National Institute for Health and Care Excellence (NICE) does not include trazodone in its first-line recommendations for depression (CG90, updated 2022), which favor SSRIs. NICE guideline NG215 for insomnia in adults does not recommend trazodone, noting insufficient evidence for a formal endorsement. The British National Formulary (BNF) lists trazodone under "antidepressant drugs" with no separate insomnia indication [13]. Off-label sleep prescribing occurs in UK general practice, though at lower rates than in North America.

Controlled Drug Status

Trazodone is not a controlled drug under the UK Misuse of Drugs Act 1971 or the Misuse of Drugs Regulations 2001. It does not require the special prescription-writing requirements that apply to Schedule 2 or Schedule 3 controlled drugs. This places it in the same regulatory tier as SSRIs and other non-controlled antidepressants [12].

Mechanism of Action: How Trazodone Works

Trazodone belongs to the serotonin antagonist and reuptake inhibitor (SARI) class. Its pharmacology is dose-dependent, which directly explains why low doses promote sleep while higher doses treat depression.

Receptor Binding at Low Doses

At doses of 25 to 100 mg (the typical insomnia range), trazodone's dominant pharmacologic action is antagonism of the 5-HT2A serotonin receptor and the histamine H1 receptor. The 5-HT2A blockade reduces cortical arousal, while H1 antagonism produces sedation. Alpha-1 adrenergic blockade also contributes to the sedating profile at these doses [14]. Serotonin reuptake inhibition is minimal at low doses because the serotonin transporter (SERT) has a lower binding affinity for trazodone compared to the 5-HT2A receptor.

Dose-Dependent Serotonergic Effects

At antidepressant doses (150 to 400 mg daily), SERT occupancy increases substantially. A positron emission tomography (PET) study by Owens et al. Demonstrated that trazodone achieves approximately 80% SERT occupancy at 300 mg daily, comparable to therapeutic SSRI occupancy levels [15]. This dual-action profile, sedation at low doses plus serotonergic antidepressant effects at higher doses, is pharmacologically distinct from SSRIs, which have minimal direct 5-HT2A activity.

Meta-chlorophenylpiperazine (mCPP) Metabolite

Trazodone is hepatically metabolized via CYP3A4 to its active metabolite meta-chlorophenylpiperazine (mCPP), a 5-HT2C agonist. MCPP can produce anxiety and dysphoria at high concentrations, which partially explains why some patients experience activation or agitation during trazodone dose titration [16]. CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) can increase mCPP formation, a clinically relevant drug interaction that the FDA label addresses with a dose-reduction recommendation [2].

Comparative Regulatory Summary Across Jurisdictions

The four major English-speaking regulatory jurisdictions agree on core points but diverge on formulation access and guideline positioning.

Points of Agreement

All four regulators (FDA, EMA member states, Health Canada, MHRA) classify trazodone as prescription-only. None have approved an insomnia indication. None schedule trazodone as a controlled substance. All recognize major depressive disorder as the sole or primary authorized indication [1][6][9][12].

Key Differences

Formulation access varies the most. The US market has only immediate-release tablets. The EU (particularly Italy and Portugal) offers extended-release Contramid tablets and oral solution formulations. The UK provides capsules and liquid formulations not available in the US. Canada's market closely mirrors the US with immediate-release tablets only [6][12].

Guideline endorsement also differs. The American Academy of Sleep Medicine (AASM) conditionally recommends against trazodone for chronic insomnia in its 2017 clinical practice guideline, citing insufficient evidence [17]. NICE similarly declines to recommend it for insomnia. The APA's 2010 practice guideline for MDD lists trazodone as a second-line antidepressant option. These guideline positions have not deterred off-label prescribing in any jurisdiction.

Evidence Gaps Driving Regulatory Caution

The absence of an insomnia indication across all four jurisdictions reflects a specific evidence deficit rather than safety signals.

Trial Limitations

Mendelson's 2005 review identified only a small number of randomized controlled trials evaluating trazodone for primary insomnia, most with fewer than 50 participants and durations under 4 weeks [3]. A 2017 systematic review by Yi et al. In the Journal of Clinical Pharmacy and Therapeutics found only seven RCTs meeting inclusion criteria, with a pooled analysis suggesting modest improvements in subjective sleep quality but no consistent benefit on objective polysomnographic measures [18]. The total evidence base remains far below the threshold that any major regulator would require for a new indication submission.

Why No Manufacturer Has Sought Approval

Trazodone's patent expired decades ago. No generic manufacturer has financial incentive to fund the large Phase III trials (typically two adequate and well-controlled studies, each with several hundred participants over 3 to 6 months) that the FDA would require for an insomnia indication [2]. The cost of such a program, estimated at $50 to $100 million, cannot be recouped when the drug is already available as a low-cost generic prescribed freely off-label. This economic reality, not a clinical safety concern, is the primary barrier to formal regulatory expansion.

Ongoing Research

The TRAZODONE-ALZ trial (NCT03460886), a European multicenter RCT, is investigating trazodone 50 mg for sleep disturbances in Alzheimer's disease. If positive, the results could generate renewed regulatory interest in a sleep-related indication, though the study population (Alzheimer's patients) would limit the generalizability of any resulting label change [19].

Practical Implications for Prescribers and Patients

Regulatory status shapes access, cost, and clinical documentation in measurable ways across these four markets.

A US prescriber writing trazodone 50 mg at bedtime for insomnia faces no legal barrier. The prescription is filled as a standard non-controlled medication, typically costing $4 to $15 for a 30-day supply at generic pricing [4]. No prior authorization is required by most commercial or Medicare Part D plans. The off-label nature of the prescription does not appear on the patient's pharmacy receipt.

A Canadian prescriber writing the same prescription operates under a stricter documentation expectation. The pharmacy record may note the off-label use, and provincial formularies may require documentation of the clinical rationale [9].

In the UK, a GP prescribing trazodone for insomnia would be working outside NICE guidance, which could create medicolegal exposure if an adverse event occurs. The lower rate of off-label trazodone insomnia prescribing in the UK compared to North America may partly reflect this regulatory environment [13].

Across all four jurisdictions, trazodone's non-controlled status remains its strongest regulatory advantage for insomnia prescribing. Patients with substance use disorder histories, those in opioid treatment programs, and those who have failed or declined benzodiazepine receptor agonists represent populations where trazodone's regulatory profile makes it a pragmatic choice, even without a formal indication [5][17].